[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332077-105":59,"doc-detail-332077-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","patient-reported-outcomes-with-selpercatinib-treatment-in-patients-with-ret-driven-cancers-in-the-phase-iii-libretto-001-trial-original-research","Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial - Original Research","","Post-hoc retrospective analysis evaluates long-term patient-reported outcomes for RET-altered non-small-cell lung cancer, medullary thyroid cancer, non-medullary thyroid cancer, and tumor-agnostic patients from the phase I/II LIBRETTO-001 trial (data cut-off January 2023). EORTC QLQ-C30 and, for MTC, modified mSTIDAT quantify baseline status and changes after selpercatinib. Results summarize improvement, stability, or worsening and time-to-first improvement or worsening with duration metrics at 2 and 3 years.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-reported-outcomes-with-selpercatinib-treatment-in-patients-with-ret-driven-cancers-in-the-phase-iii-libretto-001-trial-original-research/332077/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-reported-outcomes-with-selpercatinib-treatment-in-patients-with-ret-driven-cancers-in-the-phase-iii-libretto-001-trial-original-research/332077.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient-reported outcome measures were used in the study?","Question",{"text":112,"@type":113},"The study used the EORTC QLQ-C30 questionnaire for patients. Patients with medullary thyroid cancer also completed a modified Systemic Therapy-Induced Diarrhea Assessment Tool (mSTIDAT).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were changes in patient status after baseline reported?",{"text":117,"@type":113},"The study reports the proportion of patients whose status improved, remained stable, or worsened after baseline, with PRO summaries at 2 years or 3 years depending on cohort.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study conclude about quality of life on long-term selpercatinib?",{"text":121,"@type":113},"Most patients with RET-driven cancers improved or remained stable across most QLQ-C30 domains, indicating favorable health-related quality of life during long-term selpercatinib treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},332077,1790160424,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","ORIGINAL RESEARCH  \nPatient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial5  \nL. E. Raez1, H. Kang2, Y. Ohe3, M. Khanal4, Y. Han4, S. Szymczak5, S. S. Barker6 & A. M. Gilligan7 􀀁  \n1Memorial Cancer Institute/Florida Atlantic University (FAU), Thoracic Oncology, Boca Raton, Florida, USA; 2Department of Medicine, University of California, San Francisco, San Francisco, USA; 3National Cancer Center Hospital, Department of Thoracic Oncology, Tokyo, Japan; 4Real World and Access Analytics, Statistics, Eli Lilly and Company, Indianapolis, USA; 5Clinical Research, Oncology, Eli Lilly and Company Poland, Lilly Corporate Center, Indianapolis, USA; 6Medical Affairs, Eli Lilly and Company, Indianapolis, USA; 7Value Evidence Outcomes Research and Oncology, Eli Lilly and Company, Indianapolis, USA  \nAvailable online xxx  \nBackground: This post-hoc retrospective study describes long-term patient-reported outcomes (PROs) for REarranged during Transfection (RET)-altered non-small-cell lung cancer (NSCLC), medullary thyroid cancer (MTC), non-MTC thyroid cancer (TC), and tumor agnostic (TA) patients (Data cut-off: January 2023) from the LIBRETTO-001 trial.  \nPatients and methods: Patients completed the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) . Patients with MTC also completed a modified version of the Systemic Therapy-Induced Diarrhea Assessment Tool (mSTIDAT) . The proportion of patients with improved, stable, or worsened status after baseline was reported. PROs were summarized at 3 years (cycle 37) post-baseline for the NSCLC and MTC cohorts, and at 2 years (cycle 25) post-baseline for the TC and TA cohorts. Time-to-event outcomes (time to first improvement or worsening and duration of improvement) were reported.  \nResults: The baseline assessment was completed by 200 (63 .3%), 209 (70 .8%), 50 (76 .9%), and 38 (73 . 1%) patients in the NSCLC, MTC, TC, and TA cohorts, respectively. The total compliance rate was 80%, 82%, 70%, and 85%, respectively. Approximately 75%(NSCLC), 81%(MTC), 75%(TC), and 40%(TA) of patients across all cohorts reported improved or stable QLQ-C30 scores at year 3 (NSCLC and MTC) or year 2 (TC and TA) with continuous selpercatinib use. Across cohorts, the median time to first improvement ranged from 2 .0 to 19 .4 months, the median duration of improvement ranged from 1 .9 to 28 . 2 months, and the median time to first worsening ranged from 5 .6 to 44 .2 months. The total compliance rate for the mSTIDAT was 83 .7% and the proportion of patients with MTC who reported diarrhea on the mSTIDAT was reduced from 80 .8% at baseline to 35 .6% at year 3 .  \nConclusions: A majority of patients with RET-driven cancers improved or remained stable on most QLQ-C30 domains, demonstrating favorable health-related quality of life as measured by the QLQ-C30 during long-term treatment with selpercatinib.  \nKey words: rearranged during transfection (RET), selpercatinib, patient-reported outcomes (PROs), health-related quality of life (HRQoL), non-small-cell lung cancer (NSCLC), medullary thyroid cancer (MTC), tumor agnostic (TA)  \nINTRODUCTION  \nOncogenic alterations in REarranged during Transfection (RET), a receptor tyrosine kinase, manifest in several cancers including non-small-cell lung cancer (NSCLC), medullary thyroid cancer (MTC), papillary thyroid cancer (TC), and tumor-agnostic non-lung, non-thyroid solid cancers (TA) .1  \n*Correspondence to: Dr Adrienne M. Gilligan, Eli Lilly and Company, Indianapolis, IN, USA  \nE-mail: [gilligan_adrienne@lilly.com](gilligan_adrienne@lilly.com) (A. M. Gilligan).  \n5Note: Previous presentation: A portion of these results were presented atthe European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain (Poster \\# 669P; October 20-24, 2023).  \n2059-7029/© 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Onco","cbCainDHVgO4tBWR","https://ap.wps.com/l/cbCainDHVgO4tBWR","pdf",405473,"English","# Background\n# Patients and methods\n# Results\n# Conclusions\n# Key words\n# INTRODUCTION","[{\"question\":\"What patient-reported outcome measures were used in the study?\",\"answer\":\"The study used the EORTC QLQ-C30 questionnaire for patients. Patients with medullary thyroid cancer also completed a modified Systemic Therapy-Induced Diarrhea Assessment Tool (mSTIDAT).\"},{\"question\":\"How were changes in patient status after baseline reported?\",\"answer\":\"The study reports the proportion of patients whose status improved, remained stable, or worsened after baseline, with PRO summaries at 2 years or 3 years depending on cohort.\"},{\"question\":\"What did the study conclude about quality of life on long-term selpercatinib?\",\"answer\":\"Most patients with RET-driven cancers improved or remained stable across most QLQ-C30 domains, indicating favorable health-related quality of life during long-term selpercatinib treatment.\"}]","Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial - Original Research | PDF",1789996645,23]